Full-Time

Prod Inventory & Control Clerk

LivaNova

LivaNova

1,001-5,000 employees

Global cardiopulmonary and neuromodulation devices

Compensation Overview

$19.50 - $21/hr

Wheat Ridge, CO, USA

In Person

Category
Clerical & Data Entry (1)

Get referred to LivaNova

See people who can refer or advise you

Requirements
  • High school diploma or GED required
  • Associate degree in Supply Chain, Logistics, Business, or related field preferred
  • Minimum of 1–3 years of relevant inventory, production, or warehouse experience may substitute for post-secondary education
  • Basic proficiency with BPCS/TWS systems and Microsoft Office required
  • On-the-job training or company-specific systems certification must be completed within the first 90 days
  • Experience with barcode scanning or RF systems
  • Familiarity with lean manufacturing or inventory control best practices
  • Basic mechanical aptitude and attention to detail
  • Willingness to learn and adapt in a regulated medical-device manufacturing environment
  • Controlled manufacturing environment with adherence to strict quality, safety, and regulatory standards
  • May involve use of small tools, assembly equipment, and exposure to chemical materials with proper training and safety controls
  • Must be fluent in English, including reading, writing, speaking, and understanding English for safety, quality, documentation, and training purposes
  • Ability to lift up to 30–35 pounds
  • Ability to stand and/or walk up to 10 hours per day
  • Ability to perform initial push/pull force ≤ 35 lbs. and sustained push/pull force ≤ 18 lbs.
  • Ability to perform repetitive reaching, pinching, pulling, and neck flexion for extended periods (up to 10 hours per day)
  • Visual acuity requirements include near, distance, and color vision
  • Ability to work in a cleanroom environment
  • Ability to tolerate exposure to solvents, chemicals, fumes, or odors consistent with manufacturing operations
  • Travel none
Responsibilities
  • Maintain and update inventory records in BPCS/TWS or inventory management systems
  • Monitor stock levels and report shortages, overages, or discrepancies
  • Support production by ensuring materials are issued, staged, and available as required
  • Perform regular cycle counts and assist with physical inventory audits
  • Investigate and resolve inventory variances
  • Record and track work orders, production output, and material usage
  • Coordinate with purchasing and suppliers for material replenishment
  • Label, organize, and store inventory in an efficient and accessible manner
  • Generate reports on inventory levels, usage, and production activity
  • Follow company procedures for inventory control and quality standards
  • Record and track work orders, production output, and material usage
Desired Qualifications
  • Empowered Accountability – Take ownership of your work quality, compliance, and outcomes while acting responsibly within established standards
  • Curious Mindset – Demonstrate eagerness to learn new processes, ask questions, and seek continuous improvement
  • Thoughtful Humility & Collaborative Approach – Remain open to feedback, respect diverse perspectives, and work constructively with your team to achieve shared goals

LivaNova focuses on cardiopulmonary and neuromodulation medical technologies, delivering devices and therapies for heart and brain conditions. Its products, used in hospitals worldwide, include implants and related treatments that aim to improve patient health while providing clinical and economic value to healthcare systems. The company differentiates itself with a diverse, integrated portfolio backed by decades of experience and a global reach, aligning clinical outcomes with economic impact. Its goal is to improve patients’ lives by delivering meaningful health benefits and helping providers achieve better value.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

2015

Get referred to LivaNova

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • MRI-compatible next-generation OSA device targets FDA filing in 2026.
  • Rechargeable battery technology extends device life to 15 years.
  • CMS coverage pursuit for treatment-resistant depression could expand VNS reimbursement.

What critics are saying

  • OSA commercialization still awaits market launch and reimbursement.
  • Third-party component shortages constrain Essenz expansion and cardiopulmonary growth.
  • CMS denial would block major treatment-resistant depression reimbursement upside.

What makes LivaNova unique

  • PolySync lifted OSPREY cumulative response to 84.5%.
  • Reprogramming converted many OSA nonresponders into responders.
  • aura6000 is FDA-approved without complete concentric collapse restrictions.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Employee Stock Purchase Plan

Flexible Work Hours

Paid Vacation

Company News

Business Wire
Mar 19th, 2026
LivaNova's aura6000 system gains FDA approval for moderate to severe obstructive sleep apnea treatment

LivaNova has received FDA premarket approval for its aura6000 System to treat adults with moderate to severe obstructive sleep apnea. The device uses proximal hypoglossal nerve stimulation for patients with an apnea-hypopnea index between 15 and 65 who cannot tolerate or have failed first-line therapies like positive airway pressure. The approval follows the OSPREY randomised controlled trial, which met its primary endpoints after six months. At 12 months, 65% of treatment patients achieved responder status, defined as at least 50% improvement from baseline and an AHI below 20. LivaNova is preparing a next-generation device for FDA submission featuring MRI compatibility, remote configuration and rechargeable battery technology lasting up to 15 years. The company plans to commercialise the advanced system next year.

Yahoo Finance
Feb 25th, 2026
LivaNova reports Q4 2025 results with fifth consecutive year of double-digit EPS growth

LivaNova, a medical device company, held its fourth-quarter and full-year 2025 earnings call, reporting strong financial performance. The company delivered double-digit revenue growth, expanded adjusted operating margins and generated robust cash flow across its cardiopulmonary and epilepsy businesses. CEO Vladimir Makatsaria highlighted that 2025 marked the company's fifth consecutive year of double-digit earnings per share growth and third straight year of double-digit organic revenue growth. The company also made progress towards financial targets outlined at its November investor day. The earnings call included executives Vladimir Makatsaria, Chief Financial Officer Alex Shvartsburg, Chief Innovation Officer Ahmet Tezel and Vice President of Investor Relations Briana Gotlin. The company posted a complementary presentation summarising key points on its investor relations website.

Yahoo Finance
Feb 25th, 2026
LivaNova posts third consecutive year of double-digit growth, targets 80% Essence heart-lung machine placements by 2026

LivaNova, a medical technology company, reported its third consecutive year of double-digit organic revenue growth in 2025, driven by its Essence heart-lung machine and cardiopulmonary consumables. The company has issued 2026 revenue guidance of 6% to 7% growth. LivaNova is transitioning focus towards high-margin markets including obstructive sleep apnea, with clinical trial device approval expected in the first half of 2026. The epilepsy business received a boost from a 48% Medicare reimbursement increase effective January 2026. The company strengthened its balance sheet by reducing debt from $628 million to $377 million. LivaNova expects to maintain adjusted operating margins above 20% whilst increasing R&D investment. A $400 million litigation payment is anticipated in the third quarter of 2026.

PR Newswire
Feb 20th, 2026
Orrum partners with LivaNova to integrate CŌRE Insights analytics with Essenz Perfusion System

Orrum Clinical Analytics has announced a strategic partnership with LivaNova USA to integrate its CŌRE Insights analytics platform with LivaNova's Essenz Perfusion System. The collaboration will enable automatic transfer of perfusion case data from Essenz to Orrum's platform for post-operative analysis and peer benchmarking. The integration, called CoreInsights for Essenz, allows perfusion teams to access continuous data capture, clinically relevant analytics measuring adherence to hospital and national benchmarks, and actionable insights on practice patterns and performance indicators. Built within a Patient Safety Organization recognised by the US Department of Health and Human Services, the platform provides secure data visualisation and analytics across the patient care continuum. The partnership aims to support evidence-based performance improvement in cardiopulmonary bypass patient management and extracorporeal care.

BioSpace
May 1st, 2024
Livanova Reports First-Quarter 2024 Results

LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended March 31, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance.Financial Summary and Highlights(1). First-quarter revenue of $294.9 million increased 12.0% on a reported basis and 12.4% on a constant-currency basis, as compared to the prior-year period. Excluding the impact of the Advanced Circulatory Support (ACS) segment wind down, revenue increased 13.5% on a constant-currency basis. First-quarter U.S. GAAP diluted loss per share was $0.78 and adjusted diluted earnings per share was $0.73